Clinical Analysis of Efficacy and Safety for FK506 after Renal Transplantation

Kim, Bum Soo; Kim, Song Cheol; Kim, Tae Hee; Han, Duck Jong

Abstract

PURPOSE: The introduction of tacrolimus (FK506) has increased the choice of immunosuppressive therapies in renal transplantation.
METHODS
We retrospectively reviewed allograft patients who had been transplanted from Jan 1998 to May 2000 in FK506 group (n=57) and CsA group (n=300) to analyze renal graft outcomes and compared its effect with that of cyclosporin (CsA).
RESULTS
There were significant differences in type of donor and HLA mismatches. Renal function in FK506 was similar to CsA group. FK506 group (n=57) was equivalent to CsA (n=300) group in biopsy-proven rejection and clinical rejection including biopsy-proven rejection, respectively (10.5%, 24.6% in FK506 group and 12.3%, 18.7% in CsA group). One year-graft survival of living donor did not show significant difference between two groups (FK506 vs. CsA: 94.44% vs. 96.75%, P=0.5557). The incidence of infection in FK506 (15.8%) group is similar to that in CsA (20%). But, death due to infectious complications was more prevalent in FK506 group (5.7%), compared with CsA group (0.7%).
CONCLUSION
In summary, many significant benefits are associated with FK506 immunosuppression in renal transplantation with increasing experience of FK506, the incidence of infectious complications can be reduced.